A study of cisplatin chemotherapy and hearing loss


  • L. Sivasankari Department of ENT, Kanyakumari Medical College, Tamil Nadu
  • Lalitha Subramanian Department of Oncology, Thoothukudi Medical College, Tamil Nadu




Cisplatin chemotherapy, Ototoxicity, Sensorineural hearing loss


Background: Various medications have been associated with ototoxicity. Platinum containing chemotherapeutic agents are associated with cochleotoxicity, characterized by high frequency hearing loss. Cisplatin and related agents are absorbed by the cochlear hair cells, resulting in ototoxicity through the production of reactive oxygen species.

Methods: About 67 patients, irrespective of the type of cancer, fit to undergo chemotherapy were considered for study after meticulous examination. Audiograms were taken prior to chemotherapy, at the end of each cycle of chemotherapy, and follow-up audiograms at 3 months and 6 months after completion of chemotherapy.  

Results: Among 37% of the patients with normal hearing, 10% of the patients developed sensorineural hearing loss after treatment. Among 63% of the patients with prior mild sensorineural hearing loss, 11.8% developed worsening of hearing after completion of treatment.

Conclusions: Audiologic monitoring is important in patients undergoing cisplatin chemotherapy and post- chemotherapy auditory monitoring is essential to rehabilitate the patients with Sensorineural hearing loss.

Author Biographies

L. Sivasankari, Department of ENT, Kanyakumari Medical College, Tamil Nadu

Associate Professor,

Department of ENT


Lalitha Subramanian, Department of Oncology, Thoothukudi Medical College, Tamil Nadu

associate professor

dept of radiation oncology


Morett JA. Clinical features of cisplatin vestibulotoxicity and hearing loss. ORL J Otorhinolaryngol Rel Spec. 1976:49:67-72.

Arora R, Thakur JS, Azad RK, Mohindroo NK, Sharma DR, Seam RK. Cisplatin based chemotherapy. Bioline International. 2016;19:509.

Ramirez-Camacho R, Garcia-Berrocal JR, Bujan J, Martin- Marero A et al. Supporting cells as a target of cisplatin induce inner ear damage: therapeutic implications. Laryngoscope. 2004;114:533-7.

Helson DJ, Okonkwo E, Anton L. Cisplatinum ototoxicity. Clin Toxicol. 1978;13:469-78.

Van der Hulst RJ, Dreschler WA, Urbanus NAM. High frequency Audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann Oto Rhinol Laryngol. 1988;97:133-7.

Weatherly RA, Owens JJ, Catlin FI, Mahoney DH. Cisplatinum Ototoxicity in Children. Laryngoscope. 1991;101:917-24.

Tange RA, Dreschler WA, van der HURST. The importance of high tone audiometry in monitoring of ototoxicity. Arch Otolaryngol. 1985;242:77-81.

Aguilar-Markulis NV, Beckly S, Priore R, Mettlin C. Auditory toxicity effects of long term cis- dichlorodiammineplatinum II therapy in genitourinary cancer patient. J Surg Oncol. 1981;16:111-23.

Fausti SA, Schechter MA, Rappaport BZ, Frey RH, Mass RE. Early detection of cisplatin toxicity. Selected case reports. Cancer. 1984;53:224-31.

Shulman JB. Ototoxicity. In: Goodhill V, ed. Ear: Diseases, Deafness, and Dizziness. Hagerstown, MD: Harper and Row; 1979: 691-704.

Schell MJ, McHaney VA, Green AA, Meyer WH. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol. 1990:8:179-80.

Rybak LP, Hussain K, Morris C, Whitworth C, Somani S. Effect of protective agents against cisplatin ototoxicity. Am J Otol. 2000;21:513-20.






Original Research Articles